The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
Open accessAbstract
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder incurring significant social and economic costs. This study uses a US administrative claims database to evaluate the effect of AD on direct healthcare costs and utilization, and to identify the most common reasons for AD patients' emergency room (ER) visits and inpatient admissions. METHODS: Demographically matched cohorts age 65 and over with comprehensive medical and pharmacy claims from the 2003-2004 MEDSTAT MarketScan Medicare Supplemental and Coordination of Benefits (COB) Database were examined: 1) 25,109 individuals with an AD diagnosis or a filled prescription for an exclusively AD treatment; and 2) 75,327 matched controls. Illness burden for each person was measured using Diagnostic Cost Groups (DCGs), a comprehensive morbidity assessment system. Cost distributions and reasons for ER visits and inpatient admissions in 2004 were compared for both cohorts. Regression was used to quantify the marginal contribution of AD to health care costs and utilization, and the most common reasons for ER and inpatient admissions, using DCGs to control for overall illness burden. RESULTS: Compared with controls, the AD cohort had more co-morbid medical conditions, higher overall illness burden, and higher but less variable costs ($13,936 s. $10,369; Coefficient of variation = 181 vs. 324). Significant excess utilization was attributed to AD for inpatient services, pharmacy, ER visits, and home health care (all p < 0.05). In particular, AD patients were far more likely to be hospitalized for infections, pneumonia and falls (hip fracture, syncope, collapse). CONCLUSION: Patients with AD have significantly more co-morbid medical conditions and higher healthcare costs and utilization than demographically-matched Medicare beneficiaries. Even after adjusting for differences in co-morbidity, AD patients incur excess ER visits and inpatient admissions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In US nursing homes, among 10 576 people with confirmed COVID-19, residents living with dementia made up 52% of COVID-19 cases; yet, accounted for 72% of all deaths (an increased risk of 1·7).262”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [262]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“By 2050, 11.6 to 16 million Americans may have AD [ 2 ].”
BackgroundInfluentialPrescribing for the Elderly Part I: Sensitivity of the Elderly to Adverse Drug Reactions*
Nolan, L., & O'Malley, K. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb01785.x · Cited by 327
Using diagnoses to describe populations and predict costs.
Ash, A. S., Ellis, R. P., Pope, G. C., Ayanian, J. Z., Bates, D. W., Burstin, H. R., Iezzoni, L. I., MacKay, E., & Yu, W. (2000) · PubMed Central · Cited by 299
Self-citationFattinger, K., Roos, M., Vergères, P., Holenstein, C., Kind, B., Masche, U., Stocker, D. N., Braunschweig, S., Kullak‐Ublick, G. A., Galeazzi, R. L., et al. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00132.x · Cited by 296
Polypharmacy in the Aged: Practical Solutions
Stewart, R. B., & Cooper, J. W. (1994) · Drugs & Aging · doi:10.2165/00002512-199404060-00002 · Cited by 183
Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare
Hill, J. W., Futterman, R., Duttagupta, S., Mastey, V., Lloyd, J. R., & Fillit, H. (2002) · Neurology · doi:10.1212/wnl.58.1.62 · Cited by 181
Clinical Diagnosis and Management of Alzheimer's Disease
(2006) · CRC Press eBooks · doi:10.3109/9780203931714 · Cited by 159
Drug‐Induced Illness as a Cause for Admission to a Community Hospital
Colt, H. G., & Shapiro, A. P. (1989) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1989.tb05498.x · Cited by 147
Cost of Alzheimer's Disease and Related Dementia in Managed‐Medicare
Gutterman, E. M., Markowitz, J. S., Lewis, B., & Fillit, H. M. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb05228.x · Cited by 143
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedThe worldwide economic impact of dementia 2010
Wimo, A., Jönsson, L., Bond, J., Prince, M., Winblad, B., & International, A. D. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.006 · Cited by 1,141
Association of Incident Dementia With Hospitalizations
Phelan, E. A., Borson, S., Grothaus, L., Balch, S., & Larson, E. B. (2012) · JAMA · doi:10.1001/jama.2011.1964 · Cited by 547
Vagelatos, N. T., & Eslick, G. D. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs012 · Cited by 320
Hospitalisation rates and predictors in people with dementia: a systematic review and meta-analysis
Shepherd, H., Livingston, G., Chan, J., & Sommerlad, A. (2019) · BMC Medicine · doi:10.1186/s12916-019-1369-7 · Cited by 232
“19), but we did not include these in our meta-analysis as we wished to examine the hospitalisation risk accounting for the potential confounding effect of physical illness; we were unable to include one other study which did not provide a specific p value or confidence interval [44].”
Background
Metadata
- Authors
- Zhao, Y., Kuo, T.-C., Weir, S., Kramer, M. S., & Ash, A. S.
- Affiliations
- Eli Lilly (United States) (US)
- University of Massachusetts Chan Medical School (US)
- Boston University (US)
- Corresponding author
- Zhao, Yang
- Venue
- BMC Health Services Research
- Published
- 2008-05-22
- Volume
- 8
- Issue
- 1
- Pages
- 108-108
- ISSN
- 1472-6963 (ISSN-L)
- PMC
- PMC2424046
- OpenAlex
- W2078824554
- Cited by
- 196
- References
- 25
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 10 · 2023: 12 · 2022: 6 · 2021: 12 · 2020: 16 · 2019: 14 · 2018: 18 · 2017: 18 · 2016: 11 · 2015: 11 · 2014: 13 · 2013: 15 · 2012: 4
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- BMC Health Services Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- OpenBU (Boston University) (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- Alzheimer's disease, health care costs, health care utilization, Medicare beneficiaries, emergency department visits, hospitalization, comorbidities, disease burden, home health care, infection hospitalization, falls
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Diagnosis-Related Groups, Emergency Medical Services, Female, Medicare, Humans, Male, Patient Admission, United States, Utilization Review, Cohort Studies, Comorbidity, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. https://app.cochat.ai/papers/10.1186/1472-6963-8-108
- The paper
- Zhao, Y., Kuo, T.-C., Weir, S., Kramer, M. S., & Ash, A. S. (2008). Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Services Research. https://doi.org/10.1186/1472-6963-8-108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.